Seattle adaptive spider technology

We highly recommend ATG for their very professional work, and the freedom and assurance of not having to mend or manage IT issues ourselves. Janet S. Owner, V. P and G. Mercer Island, Wa. Our team of IT experts work to build long term partnerships based on trust which is earned by delivering real IT services and solutions that provide exceptional long term value to your organization. Sign up for our Newsletter Subscribe. Financial Services Achieve Compliance with Confidence.

Powering the Age of Immune Medicine. Meet Adaptive. We call this Immune Medicine. Immune Medicine has the power to transform how we detect and treat disease. Our Innovation Timeline.

The adaptive immune system. Decoded and deployed by our Immune Medicine Platform. Learn More. Decoded, then deployed by our Immune Medicine Platform. Our data-driven product-development process uses the adaptive immune system as its source code.

Our products will help make disease history. Adaptive hopes to tap into the explosion of interest among biotech and pharmaceutical companies in the development of therapies that take advantage of the immune system to treat disease, a trend we discussed at length in our November cover story. Immunosequencing, which uses next generation sequencing tools to quantitatively characterize the adaptive immune system, represents a multi-billion dollar opportunity given the role the immune system plays in almost all areas of medicine.

To date, Adaptive has primarily focused on developing tools and services for researchers, and Sequenta has focused on developing similar technology for use in monitoring of minimal residual disease, or MRD, for patients with blood cancers. Adaptive and its collaborators also have released promising research on the use of immunosequencing to measure the immune response to solid tumors and to immunotherapeutic drugs designed to enhance the response to cancer, which is the fastest growing class of new drugs for cancer patients.

Willis and Dr. In addition to expanding the use of its research platform for academic and pharmaceutical researchers, the combined company will focus extensively on commercializing the technology for measuring MRD in blood cancers. Chad Robins will be presenting on behalf of the new combined company at the upcoming J.